Monte Rosa pulls in $95M to test its 'mol­e­c­u­lar glues,' and the first tar­get is GSPT1

Pro­tein degra­da­tion has been a fundrais­ing hotbed in re­cent years, with in­vestors drool­ing over the po­ten­tial to drug the “un­drug­gable.” Al­ready an in­vestor dar­ling, Monte …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER